Molecular genetics

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

Retrieved on: 
Friday, May 3, 2024
UCLA, University, Molecular genetics, University College London, Health, Kyowa Kirin, Pediatrics, Pediatric nursing, Cell, TIME, Patient, Physician, Medicine, HSC, UCL, King's College, Orchard, Therapy, Biotechnology, Pharmaceutical industry

The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/ .

Key Points: 
  • The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/ .
  • “I am incredibly humbled, privileged, and immensely proud to be included on this esteemed list of influential and accomplished people shaping the future of health care,” said Dr. Gaspar.
  • “Bobby is a visionary and authentic leader who inspires the very best in his colleagues and peers,” said Frank Thomas, president and chief operating officer of Orchard Therapeutics.
  • Congratulations, Bobby, and thank you for helping carry the mantel for the broader HSC gene therapy field.”

deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer

Retrieved on: 
Thursday, April 18, 2024
Infection, Cepheid variable, University, Molecular genetics, Medical microbiology, Marketing, MD, Brown University, Medical laboratory, Pathology, Patient, Master of Science, Microbiology, UNC Kenan–Flagler Business School, Brigham Young University, MBA, Sepsis, Pharmaceutical industry

Barcelona, Spain – 18 April 2024 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, today announces the appointments of Dr Kimberle Chapin as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer.

Key Points: 
  • Barcelona, Spain – 18 April 2024 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, today announces the appointments of Dr Kimberle Chapin as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer.
  • Jordi Carrera, Chief Executive Officer and Co-Founder of deepull, said: “Kim and Wade are joining at an important time for the business as it progresses its automated sepsis diagnostic test.
  • Previously, Kimberle worked as Chief Medical Officer at Cepheid and for 17 years she was the Director of Clinical Microbiology and Molecular Diagnostics for Infectious Diseases for Lifespan Academic Medical Center.
  • The next few months will be important as we drive forward with the development of this rapid diagnostics solution and build out our commercial strategy,” commented Wade Stevenson, Chief Marketing and Sales Officer at deepull.

Nvelop Therapeutics Announces Members of Its Scientific Advisory Board

Retrieved on: 
Thursday, May 2, 2024
Health, Genetics, Other Science, Research, Science, Biotechnology, Harvard University, Danaher Corporation, Novartis, TIL, PACE, Howard Hughes Medical Institute, MIT, Gene therapy, Broad Institute, Gene editing, Duke University, Beam Therapeutics, Microbiology, Faculty, Harvard Medical School, Mammoth Biosciences, Therapy, Thomas Dudley Cabot, Aarhus University, Molecular genetics, Hospital, Arena, Biomedical engineering, RNA, Editas Medicine, Natural science, Bluebird bio, Kite Pharma, Torque, BioMarin Pharmaceutical, Patient, Gene, HSC, Massachusetts General Hospital, Growth, Pharmaceutical industry

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the members of its scientific advisory board, bringing together a world-class group of experts from across the fields of gene therapy, gene editing and drug delivery.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today announced the members of its scientific advisory board, bringing together a world-class group of experts from across the fields of gene therapy, gene editing and drug delivery.
  • Keith Joung, M.D., Ph.D. : Dr. Joung is co-founder of Nvelop Therapeutics, and a pioneer in the development of targeted gene and epigenetic editing technologies.
  • He has co-founded multiple additional biotechnology companies, including Beam Therapeutics, Chroma Medicine, Editas Medicine, Pairwise Plants, SeQure Dx and Verve Therapeutics.
  • He is also the founder or co-founder of several biotechnology and therapeutics companies, including Beam Therapeutics, Prime Medicine, Editas Medicine, Pairwise Plants, Exo Therapeutics and Chroma Medicine.

Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer

Retrieved on: 
Wednesday, April 17, 2024
Sequence, Doctor of Philosophy, Wilfrid Sellars, University, Genomics, Molecular genetics, GSK plc, Partnership, Shire (pharmaceutical company), CNS, Endo International, Villanova University, Marketing, MBA, Oxford Biomedica, Louisiana State University, Drug discovery, Pharmaceutical industry

BOSTON, April 17, 2024 /PRNewswire/ -- Sensorium Therapeutics (Sensorium), a biotechnology company developing novel, best-in-class medicines to treat a variety of CNS diseases, today announced the appointment of Sam Rasty, Ph.D., as Chief Business Officer.

Key Points: 
  • Dr. Rasty brings 25+ years of experience in R&D, strategy, commercial, BD&L, and corporate leadership as the company advances novel, best-in-class medicines to treat CNS disorders
    BOSTON, April 17, 2024 /PRNewswire/ -- Sensorium Therapeutics (Sensorium), a biotechnology company developing novel, best-in-class medicines to treat a variety of CNS diseases, today announced the appointment of Sam Rasty, Ph.D., as Chief Business Officer.
  • "Sam's expertise will fuel our business development and commercial strategies as we continue to progress our lead programs towards the clinic," said Alexandra Glucksmann, Ph.D., Chief Executive Officer of Sensorium.
  • Dr. Rasty was most recently Chief Executive Officer of Sequence Bio, a genomics and precision medicine company in Canada, President and Chief Executive Officer of PlateletBio, a pioneering cell therapy biotechnology company in the Boston area, and Board Director of Oxford Biomedica, a UK-based gene therapy company.
  • Previously, he served as Chief Operating Officer at Homology Medicines, a genetic medicines company that he helped launch in early 2016 and transform into a fully integrated public gene therapy and gene editing company.

Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Retrieved on: 
Monday, March 11, 2024
Software, Research, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Health, QC, GPU, Utrecht University, Pharmacy, IRT, Drug discovery, Radboud University Nijmegen, Cell biology, Biomarker, Molecular genetics, Bruker, University, Ultra, University of Michigan, Proteomics, Peptide, Infection, Pulse, Neoplasm, Glycomics, Lunenfeld-Tanenbaum Research Institute, TIMS, Multimedia, Medical director, BRKR, Pathology, Medical device

At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.

Key Points: 
  • At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.
  • The rapid advances in deep, at-scale proteomics, glycomics and peptidomics research solutions complement other performance-leading life-science tools for the post-genomic era by Bruker.
  • Bruker enhances its timsTOF HT and timsTOF Ultra systems with the new software Novor v2.0 for de novo immunopeptidomic profiling.
  • Our software suite supports the analysis of PASEF data, and we are delighted that Bruker now offers it with timsTOF instruments.

Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium™

Retrieved on: 
Tuesday, January 23, 2024
RAINBOW, NPC, Glycogen storage disease, GM2, Patient, Research, GM1, Niemann–Pick disease, Gait, Science, Sleep disorder, Molecular genetics, Gangliosidosis, Safety, Central nervous system, Congress, Biomarker, Pharmacokinetics, Metabolism, Pharmaceutical industry

As well as data from PRONTO, Azafaros will present details of its Phase 2 RAINBOW study, aimed at investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of nizubaglustat in patients with GM2 gangliosidosis or NPC.

Key Points: 
  • As well as data from PRONTO, Azafaros will present details of its Phase 2 RAINBOW study, aimed at investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of nizubaglustat in patients with GM2 gangliosidosis or NPC.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO) - patients’ and caregivers’ assessments.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO)- baseline clinical data.
  • Title: A natural history study of late-infantile and juvenile GM1 and GM2 gangliosidoses (PRONTO) - evaluation of different assessments.

Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Drug development, Molecular genetics, Research, FDA, Inflammation, Roche, Doctor of Philosophy, Heidelberg University, Therapy, Gastrointestinal cancer, Plexxikon, University, Max Planck Society, Wellington Partners, Growth, Patient

"We are delighted to welcome Peter to Enterome's Board of Directors," said Dr. Pierre Bélichard, Chief Executive Officer of Enterome.

Key Points: 
  • "We are delighted to welcome Peter to Enterome's Board of Directors," said Dr. Pierre Bélichard, Chief Executive Officer of Enterome.
  • "Peter is a recognized leader in the biotech industry and his extensive experience in corporate strategy and drug development will be invaluable to Enterome’s future growth and success.
  • I’d also like to thank Roger for his invaluable contributions to Enterome during his time on the Board."
  • Dr. Hirth possesses a wealth of experience and an exceptional track record in the biopharmaceutical industry.

Nature Medicine Study Validates PredicineBEACON™ MRD Liquid Biopsy Assay in Genentech’s Phase 1b Clinical Trial of Divarasib Plus Cetuximab in CRC

Retrieved on: 
Monday, December 11, 2023
Phase, Drug resistance, Urine, Associate, Lung cancer, CRC, Medicine, Molecular genetics, MRD, Plasma, Colorectal cancer, Disease, Blood, NEJM, Liquid biopsy, Cetuximab, Liquid, Genentech, Publication, Patient, NSCLC, Medical imaging

This study validates the clinical utility of PredicineBEACON™, a personalized minimal residual disease (MRD) liquid biopsy assay, in reinforcing Genentech's Phase 1b clinical trial of Divarasib plus Cetuximab in colorectal cancer (CRC).

Key Points: 
  • This study validates the clinical utility of PredicineBEACON™, a personalized minimal residual disease (MRD) liquid biopsy assay, in reinforcing Genentech's Phase 1b clinical trial of Divarasib plus Cetuximab in colorectal cancer (CRC).
  • This study exemplifies Predicine's continued leadership in the realm of liquid biopsy technology innovation and MRD.
  • Consistent with the outcomes of the prior Phase 1 clinical trial, PredicineBEACON™ showcased remarkable biomarker results in the Phase 1b clinical trial of Divarasib Plus Cetuximab in CRC patients.
  • The enhanced antitumor activity observed in this study reinforces the clinical utility of liquid biopsy profiling in evaluating the Phase 1b clinical trial of combined therapy in CRC patients.

STRANAHAN'S COLORADO WHISKEY APPOINTS NEW HEAD BLENDER, JUSTIN ADEN

Retrieved on: 
Monday, October 9, 2023
Diamond, Diamond Peak, Michigan State University, University, Single malt, Blender, Molecular genetics, Stranahan's Colorado Whiskey, Snowflake, Distillation, Research, Ethanol, Fermentation, Specialization, Unit production manager, Beer, Liquor, MSU, Microbiology

DENVER, Oct. 9, 2023 /PRNewswire/ -- Stranahan's Colorado Whiskey©, the number one-sellingi and most-awardedii American Single Malt, is pleased to announce the appointment of Justin Aden as its first Head Blender. In this critical role, Aden will oversee the intricate process of blending, distillation, and maturation of Stranahan's diverse range of American Single Malt whiskies.

Key Points: 
  • DENVER, Oct. 9, 2023 /PRNewswire/ -- Stranahan's Colorado Whiskey©, the number one-sellingi and most-awardedii American Single Malt, is pleased to announce the appointment of Justin Aden as its first Head Blender.
  • In this critical role, Aden will oversee the intricate process of blending, distillation, and maturation of Stranahan's diverse range of American Single Malt whiskies.
  • "It is an honor to be entrusted to take the reins as the first Head Blender of beloved Stranahan's Colorado Whiskey," says Aden.
  • Along with his tenure at MSU, Aden has served as Head Distiller and Production Manager at Headframe Spirits Distilling, and as Distiller, Blender and Head of Operations at Valentine Distilling Company.

ICHNOS SCIENCES PROMOTES DEAN THOMAS TO GENERAL COUNSEL

Retrieved on: 
Tuesday, October 3, 2023
University, General counsel, Intellectual property, Research, King's College London, Associate, Master of Laws, Dean Thomas, Molecular genetics, Trace fossil classification, United Kingdom, Nursing, Dean

NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today announced the promotion of Dean Thomas to the position of General Counsel, effective immediately.

Key Points: 
  • NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology, today announced the promotion of Dean Thomas to the position of General Counsel, effective immediately.
  • "During his tenure at Ichnos, Dean has demonstrated a deep understanding of the intricacies of life sciences—and oncology foremost.
  • We are pleased to welcome him to our executive leadership team as our General Counsel," said Cyril Konto, M.D., President and CEO of Ichnos Sciences.
  • "It is a distinct privilege to continue my career with Ichnos as General Counsel, supporting our company's impressive team as we strive to develop potentially life-changing cancer therapies," said Dean.